Skip to content

PressReach

SEARCH icon
  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos
Search

SEARCH FOR AN ARTICLE

  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos

PressReach

icon

      HomeNASDAQ:AZN

      NASDAQ:AZN

      AstraZeneca’s Imfinzi Got Approved by the FDA to Treat Cancer of the Biliary Tract.
      Investing News

      AstraZeneca’s Imfinzi Got Approved by the FDA to Treat Cancer of the Biliary Tract.

      September 6, 2022
      China Approves Forxiga From AstraZeneca for Renal Disease With or Without Type 2 Diabetes
      Investing News

      China Approves Forxiga From AstraZeneca for Renal Disease With or Without Type 2 Diabetes

      September 5, 2022
      Japan Approves AstraZeneca’s Evusheld for the Treatment of COVID
      Investing News

      Japan Approves AstraZeneca’s Evusheld for the Treatment of COVID

      August 31, 2022
      Japan Approves AstraZeneca’s Request to Widen Use of 3 Drugs
      Investing News

      Japan Approves AstraZeneca’s Request to Widen Use of 3 Drugs

      August 25, 2022

       

      LATEST NEWS

      • Investing News C3.ai Faces Challenges Amid Layoffs
      • Investing News Block to Lay Off 4,000 Employees
      • Investing News CoreWeave’s 2025 Financial Performance
      • Investing News TJX Price Target Raised After Strong Quarter
      • Investing News Lowe’s Q4 2025 Earnings Analysis

      PressReach

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from PressReach.

      I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

      Market Jar Media Inc. © 2026